Paradigm Biopharma - Active year ahead with significant catalysts
Paradigm has presented its half yearly results and accounts, reflecting an active period. This included an encouraging safety review for injectable...
181 Views
Paradigm Biopharma - Funded past near-term inflection points
Cash flow figures from Paradigm Biopharmaceuticals’ latest update show that it remains funded past key near-term inflection points. In Q223,...
211 Views
Paradigm Biopharma - Adapted therapies to meet unmet demand
Paradigm Biopharmaceuticals is a late-stage Australian drug developer focused on developing injectable pentosan polysulfate sodium (PPS). The...
671 Views
Paradigm Biopharmaceuticals (PAR AU): Comfortable Funding Position Through 2024
Paradigm is raising $66M via a fully underwritten placement that will entail a proforma cash position of $108.5M to fund it into 2024. The company...
305 Views
Paradigm Biopharmaceuticals (PAR AU): Concerns Persist Amid Deteriorating Financials
Paradigm’s widened net loss and depreciated cash balance raise our concern on its capability of conducting clinical activities and regulatory...
231 Views